This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Reexams set to rise in popularity, prominence, at USPTO in 2026

By Nick Robertson ( January 16, 2026, 16:15 GMT | Comment) -- As fewer patent challengers look to the Patent Trial and Appeal Board and the inter partes review (IPR) procedure, more are instead petitioning for ex parte reexamination. That brings its own strategic advantages and disadvantages, attorneys tell MLex, while the future of IPR remains unclear.Inter partes review (IPR) petitions and institution rates at the Patent Trial and Appeal Board fell to multi-year lows in late 2025, with more practitioners turning to ex parte reexaminations (EPRs) to challenge patents....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections